Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972950 | 0.94 | GRM5 (0.40) | HRH3GRM5 | |
| SCHEMBL4704099 | 0.88 | HRH3 (0.40) | HRH3GRM5SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL4701477 | 0.87 | SMN1; SMN2 (0.42) | HRH3GRM5MAPTSMN1; SMN2RAB9A | |
| SCHEMBL974314 | 0.85 | MAPK1 (0.41) | GRM5 | |
| SCHEMBL4703857 | 0.84 | DRD2 (0.49) | HRH3GRM5SMN1; SMN2RAB9AHPGD | |
| SCHEMBL4705139 | 0.83 | GRM5 (0.43) | GRM5MAPTHSD17B10HTTSMN1; SMN2 | |
| SCHEMBL4700286 | 0.83 | NAAA (0.48) | HRH3MAPTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL972810 | 0.83 | ACKR3 (0.38) | HRH3GRM5ALDH1A1 | |
| SCHEMBL972442 | 0.81 | CA12 (0.39) | RAB9A | |
| SCHEMBL971760 | 0.81 | SMN1; SMN2 (0.39) | HRH3GRM5SMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318774-B2 | N-(3-((thiazol-2-yl)amino)propyl)-3-phenylpropiolamide, 4-(thiazol-2-yl-amino)-1-(3-phenyl-propiolyl)piperidine, for example; for preventing or treating a disorder or disease that is mediated at least in part by mGluR26 receptors, such as pain, migraines, depression, neurodegenerative diseases | GRUENENTHAL GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| US-8318774-B2 | N-(3-((thiazol-2-yl)amino)propyl)-3-phenylpropiolamide, 4-(thiazol-2-yl-amino)-1-(3-phenyl-propiolyl)piperidine, for example; for preventing or treating a disorder or disease that is mediated at least in part by mGluR26 receptors, such as pain, migraines, depression, neurodegenerative diseases | GRUENENTHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1968958-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079961-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, ABCB1, FDPS | HRH3 3883/4885GRM5 2196/4885MAPT 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.